Sanofi Comprehensive Income 2010-2024 | SNY
Sanofi comprehensive income from 2010 to 2024. Comprehensive income can be defined as the change in net assets of a business enterprise during a period from transactions and other events and circumstances from nonowner sources. It includes all changes in equity during a period except those resulting from investments by owners and distributions to owners.
- Sanofi comprehensive income for the quarter ending June 30, 2024 was $1.074B, a 145.55% increase year-over-year.
- Sanofi comprehensive income for 2023 was $-0.067B, a 104.39% decline from 2022.
- Sanofi comprehensive income for 2022 was $1.529B, a 250.78% decline from 2021.
- Sanofi comprehensive income for 2021 was $-1.014B, a 73.57% decline from 2020.
Sanofi Annual Comprehensive Income
(Millions of US $) |
| 2023 |
$-67 |
| 2022 |
$1,529 |
| 2021 |
$-1,014 |
| 2020 |
$-3,836 |
| 2019 |
$722 |
| 2018 |
$-198 |
| 2017 |
$-661 |
| 2016 |
$2,173 |
| 2015 |
$1,013 |
| 2014 |
$-1,299 |
| 2013 |
$-1,279 |
| 2012 |
$-220 |
| 2011 |
$ |
| 2010 |
$ |
| 2009 |
$ |
Sanofi Quarterly Comprehensive Income
(Millions of US $) |
| 2024-06-30 |
$1,074 |
| 2024-03-31 |
|
| 2023-12-31 |
$-67 |
| 2023-09-30 |
|
| 2023-06-30 |
$437 |
| 2023-03-31 |
|
| 2022-12-31 |
$1,529 |
| 2022-09-30 |
|
| 2022-06-30 |
|
| 2022-03-31 |
|
| 2021-09-30 |
|
| 2021-03-31 |
|
| 2020-09-30 |
|
| 2020-03-31 |
|
| 2019-09-30 |
|
| 2019-03-31 |
|
| 2018-03-31 |
|
| 2017-12-31 |
$-661 |
| 2017-09-30 |
|
| 2017-06-30 |
$228 |
| 2017-03-31 |
|
| 2016-12-31 |
$2,173 |
| 2016-09-30 |
|
| 2016-06-30 |
$611 |
| 2016-03-31 |
|
| 2015-09-30 |
|
| 2015-06-30 |
$1,098 |
| 2014-06-30 |
$-4,611 |
| 2013-06-30 |
$240 |
| 2012-06-30 |
$455 |
| 2012-03-31 |
|
| 2011-12-31 |
|
| 2011-09-30 |
|
| 2011-06-30 |
|
| 2011-03-31 |
|
| 2010-12-31 |
|
| 2010-09-30 |
|
| 2010-06-30 |
|
| 2010-03-31 |
|
| 2009-12-31 |
|
| 2009-09-30 |
|
| 2009-06-30 |
|
| 2009-03-31 |
|
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Large Cap Pharmaceutical |
$145.556B |
$46.611B |
|
Sanofi-Aventis manufactures & markets prescription drugs across countries. It focuses on major therapeutic areas such as multiple sclerosis, cardiovascular, immunology, neurology, oncology, rare blood disorders & diabetes, etc. By taking Genzyme Corporation as a subsidiary, it added products like Cerezyme, Myozyme/Lumizyme & Fabrazyme to its portfolio. Sanofi has become a major player in the CHC sector. It acquired many companies i.e. Ablynx & Bioverativ, Synthorx & Principia & Translate Bio and Kadmon. It has collaborated with companies like Regeneron among others. It develops and markets Dupixent, Kevzara & Libtayo in collaboration with Regeneron. Sanofi, along with Regeneron, is now solely responsible for Praluent marketing in & outside the U.S. Sanofi operates through 3 Global Business Units: Specialty Care (neurology & immunology, rare diseases, rare blood disorders & oncology), Vaccines & General Medicines (diabetes, cardiovascular & established products) and Consumer Healthcare, a standalone unit.
|
